Observational Study Describing the Immune Profile Induced By Pertussis Vaccines

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-04-12

Study Completion Date

2018-07-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study designed to describe the immune profile of toddlers and preschoolers with acellular priming after receiving a booster dose of pertussis vaccine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines

NCT00004799

Pertussis

COMPLETED PHASE3

A Study Exploring Whooping Cough Protection in Children and Adults

NCT03697798

Pertussis

COMPLETED PHASE4

Immunising Mums Against Pertussis 3

NCT03578120

Whooping Cough Maternal Vaccine Exposure Immunization; Infection

COMPLETED

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines

NCT00004800

Pertussis

COMPLETED PHASE3

Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)

NCT02382913

Pertussis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Whooping Cough Pertussis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: Toddlers

Non-intervention observational study. Toddlers will receive wP-containing combination vaccine as part of the national immunization schedule

No interventions assigned to this group

Group 2: Toddlers

Non-intervention observational study. Toddlers will receive an aP-containing combination vaccine as part of the national immunization schedule.

No interventions assigned to this group

Group 3: Preschooler

Non-intervention observational study. Preschoolers will receive a wP-containing combination vaccine as part of the national immunization schedule.

No interventions assigned to this group

Group 4: Preschooler

Non-intervention observational study. Preschoolers will receive an aP-containing combination vaccine as part of the national immunization schedule.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

An individual must fulfill all of the following criteria in order to be eligible for study enrollment:

Toddler Cohort:

* Aged 15 to 24 months on the day of (V01)
* Has received 3 doses of a licensed pertussis-containing vaccine for a priming series during infancy in accordance with the recommendations of the NIP or his / her primary care physician
* Has written documentation (e.g., immunization record, physician's certificate, vaccination unit registry) available to verify the receipt of 3 doses of a licensed pertussis-containing infant vaccines as per national immunization schedule
* ICF has been signed and dated by the subject's parent(s) / legally acceptable representative(s) and, if required, an independent witness, in accordance with local regulations
* Planned receipt of routine pertussis booster vaccine, preferably, on same date as, and no more than 2 days following, V01
* Participant and parent / legally acceptable representative are able to attend all scheduled visits and to comply with all study procedures

Preschooler Cohort:

* Aged 48 to 59 months on the date of V01
* Has received 4 doses of pertussis-containing combination vaccines as per national immunization schedule

Exclusion Criteria

An individual fulfilling any of the following criteria is to be excluded from study enrollment:

* Participation at the time of study enrollment or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
* Receipt of any vaccine in the 4 weeks preceding the study or planned receipt of any vaccine (other than a booster pertussis vaccine) between V01 and V03a
* Receipt of immunoglobulins, blood, or blood-derived products in the past 3 months
* Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months, or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks) within the preceding 3 months
* History of clinically- or laboratory-confirmed pertussis as per the WHO recommended case definition
* Bleeding disorder, verbal report of thrombocytopenia, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating venipuncture, in the opinion of the investigator
* Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion
* Moderate or severe acute illness/infection (in the opinion of the investigator) or febrile illness (temperature ≥ 38.0°C) at physical examination on V01 of the study. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
* Receipt of oral or injected antibiotics therapy within the 72 hours preceding the first blood draw. (Topical antibiotics and antibiotic drops are not included in this exclusion criterion).
* Identified as a natural or adopted child of the Investigator or an employee with direct involvement in the proposed study

Minimum Eligible Age

15 Months

Maximum Eligible Age

59 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes